Tests hydrochlorothiazide in adults with polycystic kidney disease
Compares hydrochlorothiazide with placebo in adults with polycystic kidney disease.
Key facts
- Who runs it
- University Medical Center Groningen
- Where
- Bordeaux, Brest, Lyon Cedex 03, Paris, and Vandoeuvre Les Nancy, FranceSee the 5 sitesAlso in 6 other countries, 20 sites
- Trial code
- NCT05373264
- EU 2022-500210-26-00
- EudraCT 2021-005612-61
- U1111-1283-3529
- Registry title
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 300 people, planned
- Started
- 31 Jul 2024
- Expected to end
- Jul 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hydrochlorothiazide 25 mg
- Placebo
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with autosomal dominant polycystic kidney disease (ADPKD) who already take a V2RA drug such as tolvaptan. It tests whether adding hydrochlorothiazide helps.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- ADPKD diagnosed by the modified Ravine criteria, with eGFR above 25 mL/min/1.73m2.
- Earlier treatment
- Must be on stable treatment with the highest tolerated dose of V2RA for at least 3 months. Must not use any diuretic.
Main reasons for not taking part
- Known intolerance to hydrochlorothiazide
- Use of any diuretic
- Low blood pressure (below 105/65mmHg) or dizziness on standing
- Uncontrolled high blood pressure (above 160/100mmHg)
- Low potassium (below 3.5 mmol/L)
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- ADPKD diagnosis (modified Ravine criteria)
- ≥18 years old
- eGFR > 25 mL/min/1.73m2
- On stable treatment with the highest tolerated dose of V2RA for a minimum of 3 months
Who cannot take part
- Uncontrolled hypertension (blood pressure >160/100mmHg)
- History of active gout on maintenance preventive treatment for gout (allopurinol, desuric and/or colchicine), defined as ≥2 episodes during the last year
- History of skin cancer (basal cell, squamous cell and melanoma)
- Hypokalemia (<3.5 mmol/L)
- Known intolerance to hydrochlorothiazide
- Use of any diuretic
- Orthostatic hypotension complaints or blood pressure <105/65mmHg during screening visit
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in France
Also in 6 other countries, 20 sites
- Pellegrin HospitalBordeaux, FranceTaking people
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
- Hospital Edouard HerriotLyon Cedex 03, FranceTaking people
- Hopital Necker Enfants MaladesParis, FranceTaking people
- CHRU De NancyVandoeuvre Les Nancy, FranceTaking people
About the trial
What the trial wants to find out
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function.
Read full original descriptionShow less
Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.
The 2 groups in the trial
- HydrochlorothiazideExisting treatment, for comparison
Oral hydrochlorothiazide 25mg, once daily, for a total of 156 weeks
Treatment: Hydrochlorothiazide 25 mg
- PlaceboPlacebo, for comparison
Matching oral placebo, once daily, for a total of 156 weeks. The placebo is inert.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
- Plain-language title
- Tests hydrochlorothiazide in adults with polycystic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05373264, who can take part
- Record updated
- 25 August 2026